@article{RefWorks:doc:59ac7919e4b07cfb2e760c36,
	author={Thomas O'Hare and William C. Shakespeare and Xiaotian Zhu and Christopher A. Eide and Victor M. Rivera and Yihan Wang and Frank Wang and Lauren T. Adrian and Tianjun Zhou and Dong Zhou and Wei-Sheng Huang and Qihong Xu and Chester A. Metcalf and Jeffrey W. Tyner and Marc M. Loriaux and Amie S. Corbin and Scott Wardwell and Yaoyu Ning and Jeffrey A. Keats and Raji Sundaramoorthi and Mathew Thomas and Joseph Snodgrass and Lois Commodore and Tomi K. Sawyer and David C. Dalgarno and Michael W. N. Deininger and Brian J. Druker and Tim Clackson},
	year={2009},
	title={{AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance}},
	journal={Cancer Cell},
	volume={16},
	number={5},
	pages={401-412},
	isbn={1535-6108},
	language={English},
	doi={10.1016/j.ccr.2009.09.028},
	pmid={19878872}
}
@article{RefWorks:doc:59ac469ce4b021c5b154adff,
	author={Michael J. Eck and Paul W. Manley},
	year={2009},
	title={{The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl}},
	journal={Current Opinion in Cell Biology},
	volume={21},
	number={2},
	pages={288-295},
	isbn={1879-0410},
	language={eng},
	doi={10.1016/j.ceb.2009.01.014}
}
@article{RefWorks:doc:59ac4236e4b07cfb2e760718,
	author={Lin Li and Na Xu and Jin-Fang Zhang and Lu-Lu Xu and Xuan Zhou and Bin-Tao Huang and Yu-Ling Li and Xiao-Li Liu},
	year={2016},
	title={{EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins}},
	journal={International journal of medical sciences},
	volume={13},
	number={5},
	pages={365},
	language={English},
	url={http://www.ncbi.nlm.nih.gov/pubmed/27226777},
	pmid={27226777}
}
@techreport{RefWorks:doc:59ac28d6e4b0831af843285f,
	author={{National Institute for Health and Care Excellence}},
	year={2016},
	title={{CDF Rapid Review: Dasatinib for the first-line treatment of chronic myeloid leukaemia (part review
of TA251) [ID1014]}},
	institution={{National Institute for Health and Care Excellence}},
	pages={31},
	url={https://www.nice.org.uk/guidance/ta426/documents/committee-papers}
}
@misc{RefWorks:doc:59ac1d9fe4b0eb7a8e729b18,
	author={{National CML Society}},
	year={2010},
	title={{Response}},
	url={http://www.nationalcmlsociety.org/living-cml/response}
}
@article{RefWorks:doc:59ac0ccce4b021c5b154a8cb,
	author={Eunice Laurent and Moshe Talpaz and Hagop Kantarjian and Razelle Kurzrock},
	year={2001},
	title={{The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis}},
	journal={Cancer Research},
	volume={61},
	number={6},
	pages={2343-2355},
	url={http://cancerres.aacrjournals.org/content/canres/61/6/2343.full.pdf}
}
@misc{RefWorks:doc:5863a9a2e4b001981459f37f,
	author={{National Institute for Health and Care Excellence}},
	year={2017},
	title={{Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | Guidance and guidelines | NICE}},
	volume={2017},
	number={17 July},
	language={eng},
	url={https://www.nice.org.uk/guidance/indevelopment/gid-ta10060}
}
@article{RefWorks:doc:5863a4b4e4b05e0ea061e44d,
	author={J. E. Cortes and D. -W Kim and J. Pinilla-Ibarz and P. le Coutre and R. Paquette and C. Chuah and F. E. Nicolini and J. F. Apperley and H. J. Khoury and M. Talpaz and J. DiPersio and D. J. DeAngelo and E. Abruzzese and D. Rea and M. Baccarani and M. C. M\"uller and C. Gambacorti-Passerini and S. Wong and S. Lustgarten and V. M. Rivera and T. Clackson and C. D. Turner and F. G. Haluska and F. Guilhot and M. W. Deininger and A. Hochhaus and T. Hughes and J. M. Goldman and N. P. Shah and H. Kantarjian},
	year={2013},
	title={{A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias}},
	journal={New England Journal of Medicine},
	volume={369},
	number={19},
	pages={1783-1796},
	isbn={0028-4793},
	doi={10.1056/NEJMoa1306494}
}
@misc{RefWorks:doc:5863a058e4b0147c58332219,
	author={Robert H. Carlson},
	year={2013},
	title={{Dasatinib-, Nilotinib-Resistant CML and ALL Respond to Ponatinib : Oncology Times}},
	journal={Oncology Times},
	pages={23-24},
	abstract={An abstract is unavailable.},
	doi={10.1097/01.COT.0000427831.75958.64}
}
@article{RefWorks:doc:585ba6dde4b05e0ea0615ea0,
	author={Yelena Krijanovski and Nicholas Donato and Hanshi Sun and Feng Meng and Alfonso Quint\'as-Cardama and Jorge E. Cort\'es and Moshe Talpaz},
	year={2008},
	title={{Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation}},
	journal={Clinical Leukemia},
	volume={2},
	number={4},
	pages={267-271}, 
	isbn={1931-6925},
	doi={10.3816/CLK.2008.n.037}
}
@article{RefWorks:doc:585b3fdee4b05e0ea0615992,
	author={Fran\c{c}ois Guilhot and Richard A. Larson and Insa Gathmann and Michele Baccarani and Francisco Cervantes and Jan J. Cornelissen and Thomas Fischer and Andreas Hochhaus and Timothy Hughes and Klaus Lechner and Johan L. Nielsen and Philippe Rousselot and Josy Reiffers and Giuseppe Saglio and John Shepherd and Bengt Simonsson and Alois Gratwohl and John M. Goldman and Hagop Kantarjian and Kerry Taylor and Gregor Verhoef and Ann E. Bolton and Renaud Capdeville and Brian J. Druker and Stephen G. O'Brien},
	year={2003},
	title={{Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia}},
	journal={New England Journal of Medicine},
	volume={348},
	number={11},
	pages={994-1004},
	isbn={0028-4793},
	doi={10.1056/NEJMoa022457}
}
@misc{RefWorks:doc:585a6f1ee4b02418eb47cc08,
	author={{National Institute for Health and Care Excellence}},
	year={2016},
	title={{Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | 3-Evidence | Guidance and guidelines | NICE}},
	volume={2016},
	number={Dec 21,},
	language={eng},
	url={https://www.nice.org.uk/guidance/ta426/chapter/3-evidence}
}
@misc{RefWorks:doc:585a6ecce4b08f4705f3869d,
	author={{National Institute for Health and Care Excellence}},
	year={2016},
	title={{Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | Guidance and guidelines | NICE}},
	volume={2016},
	number={Dec 21,},
	language={eng},
	url={https://www.nice.org.uk/guidance/ta425}
}
@misc{RefWorks:doc:585a3f40e4b02418eb47c841,
	author={{Bristol-Myers Squibb Company}},
	year={2016},
	title={{SPRYCELÂ® (dasatinib) Assist}},
	volume={2016},
	number={21 dec},
	url={https://www.sprycel.com/sprycel-assist}
}
@misc{RefWorks:doc:58565c19e4b02dcd50f4ccad,
	author={{US National Institute of Health}},
	year={2010},
	title={{Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)}},
	volume={2016},
	number={18 dec},
	url={https://clinicaltrials.gov/show/NCT01244750}
}
@article{RefWorks:doc:58564bd8e4b0f87b6b283223,
	author={Hagop M. Kantarjian and Giuseppe Saglio and Michele Baccarani and Jiri Mayer and Concepcion Boqu\'e and Neil P. Shah and Charles Chuah and Luis Casanova and Brigid Bradley-Garelik and George Manos and Andreas Hochhaus and Jorge E. Cortes},
	year={2016},
	title={{Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\"ive Chronic Myeloid Leukemia Patients Trial}},
	journal={Journal of Clinical Oncology},
	volume={34},
	number={20},
	pages={2333-2340},
	isbn={0732-183X},
	doi={10.1200/JCO.2015.64.8899}
}
@article{RefWorks:doc:58405bb8e4b0ccb837453b43,
	author={Hagop Kantarjian and Ricardo Pasquini and Nelson Hamerschlak and Philippe Rousselot and Jerzy Holowiecki and Saengsuree Jootar and Tadeusz Robak and Nina Khoroshko and Tamas Masszi and Aleksander Skotnicki and Andrzej Hellmann and Andrey Zaritsky and Anatoly Golenkov and Jerald Radich and Timothy Hughes and Athena Countouriotis and Neil Shah},
	year={2007},
	title={{Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial}},
	journal={Blood},
	volume={109},
	number={12},
	pages={5143-5150},
	isbn={0006-4971},
	language={ENG},
	doi={10.1182/blood-2006-11-056028}
}
@book{RefWorks:doc:58405231e4b0c3b530632ef6,
	author={G. Rogers and M. Hoyle and J. Thompson Coon and T. Moxham and Z. Liu and M. Pitt and K. Stein},
	year={2012},
	title={{Cost-effectiveness: chronic myeloid leukaemia in chronic phase}},
	publisher={NIHR Journals Library},
	address={Southampton, UK},
	language={en},
	url={https://www.ncbi.nlm.nih.gov/books/NBK98825/}
}
@article{RefWorks:doc:58403a89e4b088d36ea8c1b1,
	author={Brian L. Abbott},
	year={2012},
	title={{Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia}},
	journal={Clinical Therapeutics},
	volume={34},
	number={2},
	pages={272-81},
	isbn={0149-2918},
	language={English},
	doi={//dx.doi.org/10.1016/j.clinthera.2012.01.009}
}
@article{RefWorks:doc:583f783be4b088d36ea8a266,
	author={Hagop Kantarjian and Neil P. Shah and Andreas Hochhaus and Jorge Cortes and Sandip Shah and Manuel Ayala and Beatriz Moiraghi and Zhixiang Shen and Jiri Mayer and Ricardo Pasquini and Hirohisa Nakamae and Fran\c{c}oise Huguet and ConcepciÃÂ³n BoquÃÂ© and Charles Chuah and Eric Bleickardt and M. Brigid Bradley-Garelik and Chao Zhu and Ted Szatrowski and David Shapiro and Michele Baccarani},
	year={2010},
	title={{Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia}},
	journal={New England Journal of Medicine},
	volume={362},
	number={24},
	pages={2260-2270},
	isbn={0028-4793},
	doi={10.1056/NEJMoa1002315}
}
@inproceedings{RefWorks:doc:583f7741e4b0c3b530630106,
	author={M. J. Mauro and M. Baccarani and F. Cervantes and J. H. Lipton and Y. Matloub and R. Sinha and R. M. Stone},
	editor={M. J. Mauro and M. Baccarani and F. Cervantes and J. H. Lipton and Y. Matloub and R. Sinha and R. M. Stone},
	year={2008},
	title={{Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)}},
	booktitle={{ASCO Annual Meeting Proceedings}},
	publisher={American Society of Clinical Oncology},
	address={Orlando, Florida},
	volume={26},
	chapter={15_suppl},
	pages={7009},
}
@article{RefWorks:doc:583dbc80e4b066125b21f1e0,
	author={E. Loveman and K. Cooper and J. Bryant and J. L. Colquitt and G. K. Frampton and A. Clegg},
	year={2012},
	title={{Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation}},
	journal={Health Technology Assessment (Winchester, England)},
	volume={16},
	number={23},
	pages={137},
	isbn={2046-4924},
	language={ENG},
	doi={10.3310/hta16230}
}
@article{RefWorks:doc:583c13cee4b027b9d41589ed,
	author={A. Olivieri and L. Manzione},
	year={2007},
	title={{Dasatinib: a new step in molecular target therapy}},
	journal={Annals of Oncology},
	volume={18},
	number={suppl 6},
	pages={vi46},
	isbn={0923-7534,15698041},
	language={en},
	doi={10.1093/annonc/mdm223}
}
@article{RefWorks:doc:583b75b4e4b027b9d415738f,
	author={C. M. Lucas and L. Wang and G. M. Austin and K. Knight and S. J. Watmough and K. H. Shwe and R. Dasgupta and Nauman M. Butt and D. Galvani and C. F. Hoyle and J. R. C. Seale and R. E. Clark},
	year={2008},
	title={{A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials}},
	journal={Leukemia},
	volume={22},
	number={10},
	pages={1963-1966},
	isbn={1476-5551},
	language={ENG},
	doi={10.1038/leu.2008.225}
}
@article{RefWorks:doc:583b750ce4b04961d35942e2,
	author={Michele Baccarani and Michael W. Deininger and Gianantonio Rosti and Andreas Hochhaus and Simona Soverini and Jane F. Apperley and Francisco Cervantes and Richard E. Clark and Jorge E. Cortes and TODO R. Hehlman},
	year={2013},
	title={{European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013}},
	journal={Blood},
	volume={122},
	number={6},
	pages={872-884},
	pmid={23803709}
}
@article{RefWorks:doc:583b6dbde4b09a21e938a834,
	author={David Marin and Alexandra Bazeos and Francois-Xavier Mahon and Lina Eliasson and Dragana Milojkovic and Marco Bua and Jane F. Apperley and Richard Szydlo and Ritti Desai and Kasia Kozlowski and Christos Paliompeis and Victoria Latham and Letizia Foroni and Mathieu Molimard and Alistair Reid and Katy Rezvani and Hugues de Lavallade and Cristina Guallar and John Goldman and Jamshid S. Khorashad},
	year={2010},
	title={{Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib}},
	journal={Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology},
	volume={28},
	number={14},
	pages={2381-2388},
	isbn={1527-7755},
	language={ENG},
	doi={10.1200/JCO.2009.26.3087}
}
@article{RefWorks:doc:583b6510e4b09a21e938a599,
	author={N. Widmer and L. A. Decosterd and C. Csajka and S. Leyvraz and M. A. Duchosal and A. Rosselet and B. Rochat and C. B. Eap and H. Henry and J. Biollaz and T. Buclin},
	year={2006},
	title={{Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein}},
	journal={British Journal of Clinical Pharmacology},
	volume={62},
	number={1},
	pages={97-112},
	isbn={0306-5251},
	language={ENG},
	doi={10.1111/j.1365-2125.2006.02719.x}
}
@article{RefWorks:doc:583b61bae4b066125b215b1c,
	author={Dale Bixby and Moshe Talpaz},
	year={2009},
	title={{Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance}},
	journal={Hematology. American Society of Hematology. Education Program},
	volume={2009},
	number={1},
	pages={461-476},
	isbn={1520-4383},
	language={ENG},
	doi={10.1182/asheducation-2009.1.461}
}
@article{RefWorks:doc:583b5ff3e4b066125b215aad,
	author={T. Raja},
	year={2012},
	title={{Optimizing second-line therapy for chronic myeloid leukemia}},
	journal={Indian Journal of Cancer},
	volume={49},
	number={1},
	pages={46},
	isbn={0019-509X},
	language={en},
	doi={10.4103/0019-509X.98918}
}
@article{RefWorks:doc:583b5731e4b066125b21592c,
	author={M. W. Deininger and J. M. Goldman and N. Lydon and J. V. Melo},
	year={1997},
	title={{The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells}},
	journal={Blood},
	volume={90},
	number={9},
	pages={3691-3698},
	isbn={0006-4971},
	language={ENG}
}
@article{RefWorks:doc:583b5609e4b066125b215900,
	author={Pavan Kumar Bhamidipati and Hagop Kantarjian and Jorge Cortes and A. Megan Cornelison and Elias Jabbour},
	year={2013},
	title={{Management of imatinib-resistant patients with chronic myeloid leukemia}},
	journal={Therapeutic Advances in Hematology},
	volume={4},
	number={2},
	pages={103-117},
	isbn={2040-6207},
	doi={10.1177/2040620712468289}
}
@misc{RefWorks:doc:583b55b1e4b066125b2158e1,
	author={{National Institute for Health and Care Excellence}},
	year={2012},
	title={{Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance | Guidance and guidelines | NICE}},
	volume={2016},
	number={Nov 27,},
	language={eng},
	url={https://www.nice.org.uk/guidance/ta241?unlid=3357119142016123195054}
}
@article{RefWorks:doc:583b1deae4b066125b214f4e,
	author={Carlo Gambacorti-Passerini and Laura Antolini and Fran\c{c}ois-Xavier Mahon and Francois Guilhot and Michael Deininger and Carmen Fava and Arnon Nagler and Chiara Maria Della Casa and Enrica Morra and Elisabetta Abruzzese and Anna D'Emilio and Fabio Stagno and Philipp le Coutre and Rafael Hurtado-Monroy and Valeria Santini and Bruno Martino and Fabrizio Pane and Andrea Piccin and Pilar Giraldo and Sarit Assouline and Muheez A. Durosinmi and Onno Leeksma and Enrico Maria Pogliani and Miriam Puttini and Eunjung Jang and Josy Reiffers and Maria Grazia Valsecchi and Dong-Wook Kim},
	year={2011},
	title={{Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib}},
	journal={Journal of the National Cancer Institute},
	volume={103},
	number={7},
	pages={553-561},
	isbn={1460-2105},
	language={ENG},
	doi={10.1093/jnci/djr060}
}
@misc{RefWorks:doc:583b173fe4b066125b214e79,
	author={{NHS Choices}},
	year={2016},
	title={{Chronic myeloid leukaemia - Treatment - NHS Choices}},
	volume={2016},
	number={Nov 27,},
	language={eng},
	url={http://www.nhs.uk/Conditions/Leukaemia-chronic/Pages/Treatment.aspx}
}
@misc{RefWorks:doc:583b0619e4b066125b214bec,
	author={David Fitz},
	year={2015},
	title={{10 Facts about CML}},
	volume={2016},
	number={Nov 27,},
	language={und},
	url={http://www.cmlsupport.org.uk/section/10-facts-about-cml}
}
@article{RefWorks:doc:583b01e7e4b04961d3592edb,
	author={E. Buchdunger and J. Zimmermann and H. Mett and T. Meyer and M. M\"uller and U. Regenass and N. B. Lydon},
	year={1995},
	title={{Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.}},
	journal={Proceedings of the National Academy of Sciences},
	volume={92},
	number={7},
	pages={2558-2562},
	isbn={0027-8424,10916490},
	language={en},
	doi={10.1073/pnas.92.7.2558}
}
@misc{RefWorks:doc:583af437e4b027b9d4155dc5,
	author={{American Society of Clinical Oncology}},
	year={2012},
	title={{Leukemia - Chronic Myeloid - CML: Phases}},
	volume={2016},
	number={Nov 27,},
	url={http://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml/phases}
}
@article{spatchcock,
	author={Zonghan Dai and Robert C. Quackenbush and Kevin D. Courtney and Matthew Grove and David Cortez and Gary W. Reuther and Ann Marie Pendergast},
	year={1998},
	title={{Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway}},
	journal={Genes \& Development},
	volume={12},
	number={10},
	pages={1415-1424},
	isbn={0890-9369,15495477},
	language={en},
	doi={10.1101/gad.12.10.1415}
}
@article{RefWorks:doc:5839ab0ce4b027b9d4153445,
	author={Gerard I. Evan and Lamorna Brown and Moira Whyte and Elizabeth Harrington},
	year={1995},
	title={{Apoptosis and the cell cycle}},
	journal={Current opinion in cell biology},
	volume={7},
	number={6},
	pages={825-834},
}
@article{RefWorks:doc:5839a9cbe4b066125b21237d,
	author={Mehran S. Neshat and Arthur B. Raitano and Hong-Gang Wang and John C. Reed and Charles L. Sawyers},
	year={2000},
	title={{The Survival Function of the Bcr-Abl Oncogene Is Mediated by Bad-Dependent and -Independent Pathways: Roles for Phosphatidylinositol 3-Kinase and Raf}},
	journal={Molecular and Cellular Biology},
	volume={20},
	number={4},
	pages={1179-1186},
	isbn={0270-7306,10985549},
	language={en},
	doi={10.1128/MCB.20.4.1179-1186.2000}
}
@article{RefWorks:doc:5839a869e4b04961d35918bf,
	author={Christian Sirard and Pierre Laneuville and John E. Dick},
	year={1994},
	title={{Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism}},
	journal={Blood},
	volume={83},
	number={6},
	pages={1575-1585},
	pmid={8123848}
}
@article{RefWorks:doc:5839a59ee4b09a21e9387fdd,
	author={M. J. Stewart and S. Litz-Jackson and G. S. Burgess and E. A. Williamson and D. S. Leibowitz and H. Scott Boswell},
	year={1995},
	title={{Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.}},
	journal={Leukemia},
	volume={9},
	number={9},
	pages={1499-1507},
	pmid={7658719}
}
@article{RefWorks:doc:5839a55ce4b027b9d41533c7,
	author={Charles L. Sawyers and Wendy Callahan and Owen N. Witte},
	year={1992},
	title={{Dominant negative MYC blocks transformation by ABL oncogenes}},
	journal={Cell},
	volume={70},
	number={6},
	pages={901-910},
}
@article{RefWorks:doc:58388287e4b027b9d4151689,
	author={Tomasz Skorski and P. Kanakaraj and M. Nieborowska-Skorska and M. Z. Ratajczak and SHAU-CHING Wen and G. Zon and A. M. Gewirtz and B. Perussia and B. Calabretta},
	year={1995},
	title={{Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells}},
	journal={Blood},
	volume={86},
	number={2},
	pages={726-736},
	pmid={7606002}
}
@article{RefWorks:doc:5838823be4b066125b210264,
	author={M. Sattler and R. Salgia and K. Okuda and N. Uemura and Ma Durstin and E. Pisick and G. Xu and Jl Li and Kv Prasad and Jd Griffin},
	year={1996},
	title={{The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.}},
	journal={Oncogene},
	volume={12},
	number={4},
	pages={839-846},
	isbn={0950-9232},
	language={eng},
	url={http://europepmc.org/abstract/med/8632906}
}
@article{RefWorks:doc:58387b12e4b066125b210151,
	author={Tarja Jonuleit and Christian Peschel and Renate Schwab and Heiko van der Kuip and Elisabeth Buchdunger and Thomas Fischer and Christoph Huber and Walter E. Aulitzky},
	year={1998},
	title={{Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors}},
	journal={British Journal of Haematology},
	volume={100},
	number={2},
	pages={295-303},
	isbn={1365-2141},
	language={en},
	doi={10.1046/j.1365-2141.1998.00564.x}
}
@article{RefWorks:doc:58387a54e4b066125b21013e,
	author={Xiaoyan Jiang and Angel Lopez and Tessa Holyoake and Allen Eaves and Connie Eaves},
	year={1999},
	title={{Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia}},
	journal={Proceedings of the National Academy of Sciences},
	volume={96},
	number={22},
	pages={12804-12809},
	isbn={0027-8424,10916490},
	language={en},
	doi={10.1073/pnas.96.22.12804}
}
@article{RefWorks:doc:5838793ee4b09a21e9385f89,
	author={Rolf P. de Groot and Jan AM Raaijmakers and Jan-Willem J. Lammers and Richard Jove and Leo Koenderman},
	year={1999},
	title={{STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells}},
	journal={Blood},
	volume={94},
	number={3},
	pages={1108-1112},
	pmid={10419904}
}
@article{RefWorks:doc:58387761e4b066125b210070,
	author={Kristen Senechal and Jocelyn Halpern and Charles L. Sawyers},
	year={1996},
	title={{The CRKL Adaptor Protein Transforms Fibroblasts and Functions in Transformation by the BCR-ABL Oncogene}},
	journal={Journal of Biological Chemistry},
	volume={271},
	number={38},
	pages={23255-23261},
	isbn={0021-9258,1083351X},
	language={en},
	doi={10.1074/jbc.271.38.23255}
}
@article{RefWorks:doc:5838765ce4b09a21e9385e58,
	author={R. Bhatia and E. A. Wayner and P. B. McGlave and C. M. Verfaillie},
	year={1994},
	title={{Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function.}},
	journal={Journal of Clinical Investigation},
	volume={94},
	number={1},
	pages={384-391},
	isbn={0021-9738},
	url={http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296320/}
}
@article{RefWorks:doc:5838763de4b09a21e9385e54,
	author={M. Y. Gordon and C. R. Dowding and G. P. Riley and J. M. Goldman and M. F. Greaves},
	year={1987},
	title={{Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia}},
	journal={Nature},
	volume={328},
	number={6128},
	pages={342-344},
	isbn={0028-0836},
	language={en},
	doi={10.1038/328342a0}
}
@article{RefWorks:doc:5836f703e4b09a21e9383112,
	author={Richard A. Van Etten and Peter Jackson and David Baltimore},
	year={1989},
	title={{The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization}},
	journal={Cell},
	volume={58},
	number={4},
	pages={669-678},
}
@article{RefWorks:doc:5836f6cee4b066125b20d2e0,
	author={Bruce J. Mayer and David Baltimore},
	year={1994},
	title={{Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.}},
	journal={Molecular and cellular biology},
	volume={14},
	number={5},
	pages={2883-2894},
	pmid={8164650}
}
@article{RefWorks:doc:5836f3b2e4b09a21e93830ca,
	author={RL Jr Ilaria and R. A. Van Etten},
	year={1995},
	title={{The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells}},
	journal={Blood},
	volume={86},
	number={10},
	pages={3897-3904},
	pmid={7579359}
}
@article{RefWorks:doc:5836f375e4b066125b20d252,
	author={D. E. Afar and Andrei Goga and Jami McLaughlin and Owen N. Witte and Charles L. Sawyers},
	year={1994},
	title={{Differential complementation of Bcr-Abl point mutants with c-Myc}},
	journal={Science},
	volume={264},
	number={5157},
	pages={424-426},
	pmid={8153630}
}
@article{RefWorks:doc:58347fcce4b066125b203f3d,
	author={EFM Posthuma and JHF Falkenburg and J. F. Apperley and A. Gratwohl and E. Roosnek and B. Hertenstein and R. F. Schipper and GMT Schreuder and J. DÃ¢ÂÂAmaro and M. Oudshoorn},
	year={1999},
	title={{HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia}},
	journal={Blood},
	volume={93},
	number={11},
	pages={3863-3865},
	pmid={10339494}
}
@article{RefWorks:doc:58347e6be4b027b9d4144c20,
	author={Shikha Bose and Michael Deininger and Joanna Gora-Tybor and John M. Goldman and Junia V. Melo},
	year={1998},
	title={{The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease}},
	journal={Blood},
	volume={92},
	number={9},
	pages={3362-3367},
	pmid={9787174}
}
@article{RefWorks:doc:58347da0e4b066125b203ed0,
	author={Michael WN Deininger and Shikha Bose and Joanna Gora-Tybor and Xiu-Hua Yan and John M. Goldman and Junia V. Melo},
	year={1998},
	title={{Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation}},
	journal={Cancer research},
	volume={58},
	number={3},
	pages={421-425},
	pmid={9458083}
}
@article{RefWorks:doc:58347d5be4b066125b203ebd,
	author={Kimio Tanaka and Miho Takechi and Joehoon Hong and Chiharu Shigeta and Nobuo Oguma and Nanao Kamada and Yasuo Takimoto and Atsushi Kuramoto and Hiroo Dohy and Taiichi Kyo},
	year={1989},
	title={{9; 22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors}},
	journal={Journal of radiation research},
	volume={30},
	number={4},
	pages={352-358},
	pmid={2614751}
}
@article{RefWorks:doc:58345fbde4b066125b203840,
	author={Junia V. Melo},
	year={1997},
	title={{2 BCR-ABL gene variants}},
	journal={Baillire's clinical haematology},
	volume={10},
	number={2},
	pages={203-222},
}
@article{RefWorks:doc:58345cc7e4b09a21e937923d,
	author={Junia V. Melo},
	year={1996},
	title={{The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment]}},
	journal={Blood},
	volume={88},
	number={7},
	pages={2375-2384},
	pmid={8839828}
}
@article{RefWorks:doc:58345bf8e4b027b9d41441c6,
	author={Jan Willem Voncken and Hermien van Schaick and Vesa Kaartinen and Kathleen Deemer and Thomas Coates and Benjamin Landing and Paul Pattengale and Olivier Dorseuil and Gary M. Bokoch and John Groffen},
	year={1995},
	title={{Increased neutrophil respiratory burst in bcr-null mutants}},
	journal={Cell},
	volume={80},
	number={5},
	pages={719-728},
}
@article{RefWorks:doc:583455c2e4b09a21e93790f8,
	author={J. Zhu and S. K. Shore},
	year={1996},
	title={{c-ABL tyrosine kinase activity is regulated by association with a novel SH3-domain-binding protein.}},
	journal={Molecular and Cellular Biology},
	volume={16},
	number={12},
	pages={7054-7062},
	isbn={0270-7306,10985549},
	language={en},
	doi={10.1128/MCB.16.12.7054}
}
@article{RefWorks:doc:5834545de4b09a21e93790d0,
	author={Richard A. Van Etten},
	year={1999},
	title={{Cycling, stressed-out and nervous: cellular functions of c-Abl}},
	journal={Trends in cell biology},
	volume={9},
	number={5},
	pages={179-186},
}
@article{RefWorks:doc:583334dae4b0de15c9d902ed,
	author={Edward T. Kipreos and Jean YJ Wangt},
	year={1992},
	title={{Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA}},
	journal={Science},
	volume={256},
	number={5055},
	pages={382}
}
@article{RefWorks:doc:58333428e4b047a10adb43f4,
	author={George B. Cohen and Ruibao Ren and David Baltimore},
	year={1995},
	title={{Modular binding domains in signal transduction proteins}},
	journal={Cell},
	volume={80},
	number={2},
	pages={237-248},
}
@article{RefWorks:doc:58309bd3e4b05b192d72d4eb,
	author={Tracy G. Lugo and Ann-Marie Pendergast and Alexander J. Muller and Owen N. Witte},
	year={1990},
	title={{Tyrosine kinase activity and transformation potency of bcr-abl oncogene products}},
	journal={Science},
	volume={247},
	number={4946},
	pages={1079-1082},
	pmid={2408149}
}
@article{RefWorks:doc:58309bb1e4b047a10adac048,
	author={John Groffen and John R. Stephenson and Nora Heisterkamp and Annelies de Klein and Claus R. Bartram and Gerard Grosveld},
	year={1984},
	title={{Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22}},
	journal={Cell},
	volume={36},
	number={1},
	pages={93-99},
	isbn={0092-8674},
	doi={10.1016/0092-8674(84)90077-1}
}
@article{RefWorks:doc:58309b92e4b05b192d72d4da,
	author={Claus R. Bartram and Annelies de Klein and Anne Hagemeijer and Ton van Agthoven and Ad Geurts van Kessel and Dirk Bootsma and Gerard Grosveld and Malcolm A. Ferguson-Smith and Teresa Davies and Marion Stone and Nora Heisterkamp and John R. Stephenson and John Groffen},
	year={1983},
	title={{Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia}},
	journal={Nature},
	volume={306},
	number={5940},
	pages={277-280},
	isbn={0028-0836},
	language={en},
	doi={10.1038/306277a0}
}
@article{RefWorks:doc:58309b12e4b047a10adac03d,
	author={P. Nowell and D. Hungerford},
	year={2004},
	title={{A minute chromosome in human chronic granulocytic leukemia}},
	journal={Landmarks in Medical Genetics: Classic Papers with Commentaries},
	volume={132},
	number={51},
	pages={103},
	url={https://books.google.co.uk/books?hl=en&lr=&id=9P2cVq-voCUC&oi=fnd&pg=PA103&ots=eiEw6csX27&sig=pkmd35-ka_JBSzW9wTl1CzO18S0&redir_esc=y#v=onepage&q&f=false}
}
@article{RefWorks:doc:58309a92e4b0de15c9d88743,
	author={Janet D. Rowley},
	year={1973},
	title={{A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining}},
	journal={Nature},
	volume={243},
	number={5405},
	pages={290-293},
	isbn={0028-0836},
	language={en},
	doi={10.1038/243290a0}
}
@article{RefWorks:doc:58309926e4b05b192d72d473,
	author={M. W. Deininger and J. M. Goldman and J. V. Melo},
	year={2000},
	title={{The molecular biology of chronic myeloid leukemia}},
	journal={Blood},
	volume={96},
	number={10},
	pages={3343-3356},
	isbn={0006-4971},
	language={ENG},
	url={http://www.bloodjournal.org/content/96/10/3343}
}
@article{RefWorks:doc:58309829e4b05b192d72d445,
	author={Anjali S. Advani and Ann Marie Pendergast},
	year={2002},
	title={{Bcr-Abl variants: biological and clinical aspects}},
	journal={Leukemia Research},
	volume={26},
	number={8},
	pages={713-720},
	isbn={0145-2126,18735835},
	language={English},
	doi={10.1016/S0145-2126(01)00197-7}
}
